MCLA-117

Date Publication
Nov 09, 2016
MCLA-117, a CLEC12AXCD3 bispecific IgG targeting a leukemic stem cell antigen, induces T cell mediated AML blast lysis

Pieter Fokko van Loo1, Henrike Veninga1, Harry Dolstra2, and Lex Bakker11Merus NV, Utrecht, Netherlands; 2Radboud University Medical Center and Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands.

Poster presented at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting, National Harbor, MD, USA.

MCLA-128

Date Publication
Oct 21, 2018
Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Maria Alsina1, Andrea Varga2, Alessio Amatu3, Jan H.M. Schellens4, Els Witteveen5, Valentina Boni6, Victor Moreno7, Paolo Nuciforo1, Aurelia de Vries Schultink4, Kees Bol8, Afrodite Lourbakos8, Marina Magin Ferrer8, and Ernesto Wasserman8. 1Vall d’Hebron University Hospital, Barcelona, Spain; 2DITEP, Gustave Roussy, Villejuif, France; 3Niguarda Hospital, Milan, Italy; 4Netherlands Cancer Institute, Amsterdam, Netherlands; 5University Medical Center Utrecht, Netherlands; 6START CIOCC, Madrid, Spain; 7START – FJD, Madrid, Spain; 8Merus NV, Utrecht, Netherlands.

Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.

May 14, 2018
Unbiased combinatorial screening identifies a bispecific IgG1 that potently inhibits HER3 signaling via HER2-guided ligand blockade

Cecile A.W. Geuijen, Camilla De Nardis, David Maussang, Eric Rovers, Tristan Gallenne, Linda J.A. Hendriks, Therese Visser, Roy Nijhuis, Ton Logtenberg, John de Kruif, Piet Gros, and Mark Throsby. Cancer Cell, 33, 922-936 (2018).

May 05, 2018
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose

Aurelia H. M. de Vries Schultink, Robert P. Doornbos, Alexander B. H. Bakker, Kees Bol, Mark Throsby, Cecile Geuijen, David Maussang, Jan H. M. Schellens, Jos H. Beijnen, and Alwin D. R. Huitema. Investigational New Drugs, 36, 1006–1015 (2018).

Jun 02, 2017
First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3; final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC)

Maria Alsina1, Valentina Boni2, Aurelia de Vries Schultink3, Victor Moreno4, Kees Bol5, Martine Westendorp5, L. Andres Sirulnik5, Josep Tabernero1, and Emiliano Calvo2.1Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; 2START Madrid CIOCC, Hospital HM Universitario Sanchinarro, Madrid, Spain; 3Netherlands
Cancer Institute, Amsterdam, Netherlands; 4START – FJD, Madrid, Spain; 5Merus NV, Utrecht, Netherlands.

Poster presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, Chicago, IL, USA.

Apr 01, 2017
The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis

David Maussang1, Camilla De Nardis2, Linda Hendriks1, Carina Bartelink-Clements1, Nellie Nieuwenhuizen1, Eric Rovers1, Tristan Gallenne1, Robert Doornbos1, Lex Bakker1, Ton Logtenberg1, John de Kruif1, Piet Gros2, Cecile Geuijen1, and Mark Throsby1.1Merus NV, Utrecht, Netherlands; 2Utrecht University, Netherlands.

Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.

MCLA-145

Date Publication
Mar 31, 2019
An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties

Cecile A. Geuijen1, Paul Tacken1, Rinse Klooster1, Horacio Nastri2, Shaun Stewart2, Jing Zhou2, Steve Wang2, Cheng-Yen Huang2, Arjen Kramer1, Linda Kaldenberg-Hendriks1, John de Kruif1, Renate den Blanken-Smit1, Vanessa Zondag-van de Zande1, Abdul Basmeleh1, Willem Bartelink1, Patrick Mayes2, Gregory Hollis2, Reid Huber2, Mark Throsby11Merus NV, Utrecht, Netherlands; 2Incyte Corporation, Wilmington, DE.

Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.

Mar 31, 2019
A bispecific Fc-silenced IgG1 antibody (MCLA-145) requires PD-L1 binding to activate CD137

Patrick Mayes1, Paul Tacken2, Steve Wang1, Pieter-Fokko van Loo2, Thomas Condamine1, Hans van der Maaden2, Eric Rovers2, Steef Engels2, Floris Fransen2, Ashwini Kulkarni1, Yao-bin Liu1, Arpita Mondal1, Leslie Hall1, Soyeon Kim3, Marina Martinez3, Shaun O’Brien3, Edmund Moon3, Steven Albelda3, Peggy Scherle1, Gregory Hollis1, Reid Huber1, Mark Throsby2, Cecile A. Geuijen21Incyte Corporation, Wilmington, DE; 2Merus NV, Utrecht, Netherlands; 3University of Pennsylvania, Philadelphia.

Poster presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting, Atlanta, GA, USA.

MCLA-158

Date Publication
Apr 01, 2017
Identification and characterisation of MCLA-158 as an anti-EGFRxLGR5 bispecific antibody that potently inhibits patient-derived CRC organoid growth

Rob C. Roovers1, Bram Herpers2, Mark James3, Berina Eppink1, Carme Cortina3, David Maussang-Detaille1, Ingrid Kolfschoten1, Sylvia F. Boy4, Marc van de Wetering4, Wim de Lau5, Robert Doornbos1, Carina Clements1, Abdul Basmeleh1, Willem Bartelink1, Vanessa Zondag van de Zande1, Kuan Yan2, Lucia Salinaro2, Lex Bakker1, John de Kruif1, Hans Clevers5, Robert Vries4, Eduard Batlle3, Leo Price2 and Mark Throsby1.1Merus NV, Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3IRB Barcelona, Spain; 4HUB, Utrecht, Netherlands; 5The Hubrecht Institute, Utrecht, Netherlands.

Poster presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, DC, USA.

Nov 04, 2015
Generation of Wnt- and mitogenic receptor binding bispecific antibodies to target cancer stem cells

Berina Eppink1, Rob Roovers1, Bram Herpers2, Wim de Lau3, Carina Clements1, Vanessa Zondag van der Zande1, Abdul Basmeleh1, Willem Bartelink1, Marc van de Wetering3,4, Robert Vries3,4, Leo Price2, John de Kruif1, and Mark Throsby11Merus BV Utrecht, Netherlands; 2OcellO BV, Leiden, Netherlands; 3Hubrecht Institute, Utrecht, Netherlands; 4HUB, Utrecht, Netherlands.

Poster presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, USA.

Technology

Date Publication
Jun 27, 2017
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1

Camilla De Nardis*, Linda J.A. Hendriks*, Emilie Poirier, Tudor Arvinte, Piet Gros, Alexander B.H. Bakker, and John de Kruif. Journal of Biological Chemistry, 292,  14706-14717 (2017).

Sep 26, 2016
Generation of immuno-modulatory receptor binding bispecific antibodies to modulate tumor immunity

Rinse Klooster, Cecile Geuijen, Renate den Blanken-Smit, Mireille Koenders, Annette Wensink, Eric Rovers, Hans van der Maaden, Steef Engels, Tristan Gallenne, Therese Visser, Carina Bartelink-Clements, Katinka van Zoest, Roy Nijhuis, Abdul Basmeleh, Willem Bartelink, Vanessa Zondag-van der Zande, Arjen Kramer, Linda Kaldenberg, Berina Eppink, Rob Roovers, Paul Tacken, Lex Bakker, Pieter Fokko van Loo, John de Kruif, and Mark Throsby.

Poster presented at the International Congress on Immunotherapies in Cancer (ICIC) 2016 Annual Meeting, New York, NY, USA.

Nov 11, 2013
Complex mixtures of antibodies generated from a single production qualitatively and quantitatively evaluated by native Orbitrap mass spectrometry

Natalie J. Thompson, Linda J.A. Hendriks, John de Kruif, Mark Throsby, and Albert J.R. Heck. mAbs, 6, 197-203 (2013).

Aug 10, 2012
Qualitative and semiquantitative analysis of composite mixtures of antibodies by native mass spectrometry

Sara Rosati, Natalie J. Thompson, Arjan Barendregt, Linda J. A. Hendriks, Alexander B. H. Bakker, John de Kruif, Mark Throsby, Esther van Duijn, and Albert J. R. Heck. Analytical Chemistry, 84, 7227–7232 (2012).

Jun 21, 2010
Generation of stable cell clones expressing mixtures of human antibodies

John de Kruif, Arjen Kramer, Roy Nijhuis, Vanessa van der Zande, Renate den Blanken, Carina Clements, Therese Visser, Rob Keehnen, Marcel den Hartog, Mark Throsby, and Ton Logtenberg. Biotechnology and Bioengineering, 106, 741-750 (2010).

Apr 03, 2009
Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous VH genes

John de Kruif, Arjen Kramer, Therèse Visser, Carina Clements, Roy Nijhuis, Freek Cox, Vanessa van der Zande, Renate Smit, Daniel Pinto, Mark Throsby, and Ton Logtenberg. Journal of Molecular Biology, 387, 548-558 (2009).